Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Rhea-AI Summary

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced the participation of CEO Anish Bhatnagar in a panel discussion at the LifeSci Partners 11th Annual Corporate Access Event on January 6, 2022. The panel, titled Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders, will take place at 2:00 PM ET. A live webcast is available at this link, and a replay can be accessed on the company’s website. Soleno is focused on developing treatments for rare diseases, notably evaluating its lead candidate for Prader-Willi Syndrome.

REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11^th Annual Corporate Access Event.

Details for the panel discussions are below:

Title:	Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders
Date:	Thursday, January 6, 2022
Time:	2:00 PM ET
Webcast:	https://wsw.com/webcast/lifesci3/panel10/2456850

A live audio webcast and replay of the panel discussion will be available in the Investors section on the Company’s website at www.soleno.life.

Members of Soleno’s management team will also be conducting one-on-one meetings with institutional investors during the event.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics' stock symbol is SLNO.

When is the LifeSci Partners Corporate Access Event featuring Soleno?

The event is on January 6, 2022.

What is the topic of the panel discussion that Soleno's CEO will participate in?

The topic is Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders.

At what time will the panel discussion take place?

The panel discussion will occur at 2:00 PM ET.

Where can I find the webcast for the Soleno panel discussion?

The webcast can be found at this link.

What is Soleno Therapeutics' lead candidate for treatment?

Soleno's lead candidate is DCCR extended-release tablets for Prader-Willi Syndrome.